Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (HK:2196)
:2196
Total Valuation
Shanghai Fosun Pharmaceutical (Group) Co has a market cap or net worth of HK$76.00B. The enterprise value is HK$98.09B.
Market CapHK$76.00B
Enterprise ValueHK$98.09B
Share Statistics
Shanghai Fosun Pharmaceutical (Group) Co has 551,940,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding551,940,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Shanghai Fosun Pharmaceutical (Group) Co’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 2.00%.
Return on Equity (ROE)0.07
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)2.00%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee996.73K
Profits Per Employee104.74K
Employee Count40,557
Asset Turnover0.34
Inventory Turnover3.24
Valuation Ratios
The current PE Ratio of Shanghai Fosun Pharmaceutical (Group) Co is 14.2. Shanghai Fosun Pharmaceutical (Group) Co’s PEG ratio is 0.74.
PE Ratio14.2
PS Ratio1.15
PB Ratio0.95
Price to Fair Value0.95
Price to FCF60.76
Price to Operating Cash Flow12.00
PEG Ratio0.74
Income Statement
In the last 12 months, Shanghai Fosun Pharmaceutical (Group) Co had revenue of 40.42B and earned 3.28B in profits. Earnings per share was 1.24.
Revenue40.42B
Gross Profit20.16B
Operating Income2.54B
Pretax Income4.98B
Net Income3.28B
EBITDA6.16B
Earnings Per Share (EPS)1.24
Cash Flow
In the last 12 months, operating cash flow was 3.97B and capital expenditures -3.35B, giving a free cash flow of 611.64M billion.
Operating Cash Flow3.97B
Free Cash Flow611.64M
Free Cash Flow per Share1.11
Dividends & Yields
Shanghai Fosun Pharmaceutical (Group) Co pays an annual dividend of HK$0.35, resulting in a dividend yield of 1.69%
Dividend Per ShareHK$0.35
Dividend Yield1.69%
Payout Ratio25.72%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.10
52-Week Price Change59.22%
50-Day Moving Average19.91
200-Day Moving Average21.01
Relative Strength Index (RSI)62.46
Average Volume (3m)8.63M
Important Dates
Shanghai Fosun Pharmaceutical (Group) Co upcoming earnings date is Apr 29, 2026, TBA (Confirmed).
Last Earnings DateMar 24, 2026
Next Earnings DateApr 29, 2026
Ex-Dividend Date―
Financial Position
Shanghai Fosun Pharmaceutical (Group) Co as a current ratio of 0.93, with Debt / Equity ratio of 75.33%
Current Ratio0.93
Quick Ratio0.76
Debt to Market Cap0.72
Net Debt to EBITDA3.82
Interest Coverage Ratio2.06
Taxes
In the past 12 months, Shanghai Fosun Pharmaceutical (Group) Co has paid 841.69M in taxes.
Income Tax841.69M
Effective Tax Rate0.17
Enterprise Valuation
Shanghai Fosun Pharmaceutical (Group) Co EV to EBITDA ratio is 11.36, with an EV/FCF ratio of 91.55.
EV to Sales1.73
EV to EBITDA11.36
EV to Free Cash Flow91.55
EV to Operating Cash Flow13.43
Balance Sheet
Shanghai Fosun Pharmaceutical (Group) Co has HK$15.78B in cash and marketable securities with HK$36.66B in debt, giving a net cash position of -HK$20.88B billion.
Cash & Marketable SecuritiesHK$15.78B
Total DebtHK$36.66B
Net Cash-HK$20.88B
Net Cash Per Share-HK$37.83
Tangible Book Value Per ShareHK$12.50
Margins
Gross margin is 49.00%, with operating margin of 6.27%, and net profit margin of 8.12%.
Gross Margin49.00%
Operating Margin6.27%
Pretax Margin12.32%
Net Profit Margin8.12%
EBITDA Margin15.25%
EBIT Margin6.27%
Analyst Forecast
The average price target for Shanghai Fosun Pharmaceutical (Group) Co is HK$35.30, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$35.30
Price Target Upside79.83% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-1.12%
EPS Growth Forecast76.16%